阿瓦德什·库马尔·辛格就文章《二肽基肽酶-4抑制剂与磺脲类药物作为2型糖尿病附加治疗的心血管结局比较：一项荟萃分析》所写的信 - Suppr

Suppr

超能文献

Letter by Awadhesh Kumar Singh Regarding Article, "Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: A Meta-Analysis".

作者信息

Singh Awadhesh Kumar, Singh Ritu

机构信息

Department of Diabetes & Endocrinology, G.D Hospital & Diabetes Institute, Kolkata, India.

出版信息

J Lipid Atheroscler. 2022 Jan;11(1):84-86. doi: 10.12997/jla.2022.11.1.84. Epub 2021 Nov 26.

DOI:10.12997/jla.2022.11.1.84

PMID:35118024

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8792819/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ebd/8792819/0f381d2fbd24/jla-11-84-g001.jpg

相似文献

Letter by Awadhesh Kumar Singh Regarding Article, "Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: A Meta-Analysis".阿瓦德什·库马尔·辛格就文章《二肽基肽酶-4抑制剂与磺脲类药物作为2型糖尿病附加治疗的心血管结局比较：一项荟萃分析》所写的信

J Lipid Atheroscler. 2022 Jan;11(1):84-86. doi: 10.12997/jla.2022.11.1.84. Epub 2021 Nov 26.

Response to Letter Regarding Article, "Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis".对关于文章《二肽基肽酶-4抑制剂与磺脲类药物作为2型糖尿病附加治疗的心血管结局比较：一项荟萃分析》的来信的回复

J Lipid Atheroscler. 2022 Jan;11(1):87-88. doi: 10.12997/jla.2022.11.1.87. Epub 2022 Jan 3.

Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis.二肽基肽酶-4抑制剂与磺脲类药物作为2型糖尿病附加治疗的心血管结局比较：一项荟萃分析

J Lipid Atheroscler. 2021 May;10(2):210-222. doi: 10.12997/jla.2021.10.2.210. Epub 2021 Jan 25.

Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.二肽基肽酶-4抑制剂与2型糖尿病患者心力衰竭风险：一项基于人群的队列研究。

Circ Heart Fail. 2017 Sep;10(9). doi: 10.1161/CIRCHEARTFAILURE.117.003957.

Efficacy and safety of a sodium-glucose co-transporter-2 inhibitor versus placebo as an add-on therapy for people with type 2 diabetes inadequately treated with metformin and a dipeptidyl peptidase-4 inhibitor: a systematic review and meta-analysis of randomised controlled trials.钠-葡萄糖共转运蛋白 2 抑制剂与安慰剂作为二甲双胍和二肽基肽酶-4 抑制剂治疗不佳的 2 型糖尿病患者的附加治疗的疗效和安全性：随机对照试验的系统评价和荟萃分析。

Diabet Med. 2021 Feb;38(2):e14409. doi: 10.1111/dme.14409. Epub 2020 Nov 28.

Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis.二肽基肽酶-4抑制剂与磺脲类药物在二甲双胍基础上联合治疗2型糖尿病的安全性和有效性：系统评价与荟萃分析

Clin Invest Med. 2016 Apr 2;39(2):E48-62. doi: 10.25011/cim.v39i2.26481.

Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.在 2 型糖尿病患者中，与磺酰脲类药物相比，添加二肽基肽酶-4 抑制剂对临床结局的影响。

Ann Intern Med. 2015 Nov 3;163(9):663-72. doi: 10.7326/M15-0308. Epub 2015 Oct 13.

Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?二肽基肽酶-4 抑制剂与 2 型糖尿病的心血管和肾脏疾病：我们从 CARMELINA 试验中学到了什么？

Diab Vasc Dis Res. 2019 Jul;16(4):303-309. doi: 10.1177/1479164119842339. Epub 2019 Apr 24.

Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis.二肽基肽酶4（DPP-4）抑制剂与2型糖尿病（T2DM）患者的心血管结局：一项系统评价和荟萃分析。

BMC Pharmacol Toxicol. 2019 Mar 4;20(1):15. doi: 10.1186/s40360-019-0293-y.

Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes.2型糖尿病患者中，二肽基肽酶4抑制剂与其他二线和三线抗糖尿病药物的心血管风险比较。

Br J Clin Pharmacol. 2017 Jul;83(7):1556-1570. doi: 10.1111/bcp.13241. Epub 2017 Feb 27.

本文引用的文献

J Lipid Atheroscler. 2021 May;10(2):210-222. doi: 10.12997/jla.2021.10.2.210. Epub 2021 Jan 25.

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.利格列汀与格列美脲对2型糖尿病患者主要不良心血管结局的影响：卡罗来纳州随机临床试验

JAMA. 2019 Sep 24;322(12):1155-1166. doi: 10.1001/jama.2019.13772.

Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data.与其他降糖药物相比，磺脲类药物相关的心血管事件和全因死亡率：生存数据的贝叶斯荟萃分析。

Diabetes Obes Metab. 2017 Mar;19(3):329-335. doi: 10.1111/dom.12821. Epub 2016 Dec 23.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验